image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 7.715
0.132 %
$ 9.21 B
Market Cap
-14.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VTRS stock under the worst case scenario is HIDDEN Compared to the current market price of 7.71 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VTRS stock under the base case scenario is HIDDEN Compared to the current market price of 7.71 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VTRS stock under the best case scenario is HIDDEN Compared to the current market price of 7.71 USD, Viatris Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VTRS

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
14.7 B REVENUE
-4.46%
10.1 M OPERATING INCOME
-98.68%
-634 M NET INCOME
-1159.41%
2.3 B OPERATING CASH FLOW
-17.74%
1.8 B INVESTING CASH FLOW
335.66%
-4.33 B FINANCING CASH FLOW
-88.12%
3.53 B REVENUE
-5.62%
-180 M OPERATING INCOME
-79.59%
-516 M NET INCOME
-544.83%
483 M OPERATING CASH FLOW
-41.60%
-169 M INVESTING CASH FLOW
-9.65%
-1.42 B FINANCING CASH FLOW
13.23%
Balance Sheet Viatris Inc.
image
Current Assets 9.52 B
Cash & Short-Term Investments 735 M
Receivables 3.22 B
Other Current Assets 5.56 B
Non-Current Assets 32 B
Long-Term Investments 1.35 B
PP&E 2.67 B
Other Non-Current Assets 28 B
7.76 %13.41 %3.25 %6.42 %67.38 %Total Assets$41.5b
Current Liabilities 5.78 B
Accounts Payable 1.36 B
Short-Term Debt 87.7 M
Other Current Liabilities 4.34 B
Non-Current Liabilities 17.1 B
Long-Term Debt 16 B
Other Non-Current Liabilities 1.11 B
5.93 %18.96 %69.88 %4.85 %Total Liabilities$22.9b
EFFICIENCY
Earnings Waterfall Viatris Inc.
image
Revenue 14.7 B
Cost Of Revenue 9.12 B
Gross Profit 5.62 B
Operating Expenses 5.61 B
Operating Income 10.1 M
Other Expenses 644 M
Net Income -634 M
16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)15b(9b)6b(6b)10m(644m)(634m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
38.15% GROSS MARGIN
38.15%
0.07% OPERATING MARGIN
0.07%
-4.30% NET MARGIN
-4.30%
-3.40% ROE
-3.40%
-1.53% ROA
-1.53%
0.03% ROIC
0.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Viatris Inc.
image
3b3b3b3b2b2b2b2b1b1b500m500m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -634 M
Depreciation & Amortization 2.89 B
Capital Expenditures -326 M
Stock-Based Compensation 146 M
Change in Working Capital 0
Others 665 M
Free Cash Flow 1.98 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Viatris Inc.
image
Wall Street analysts predict an average 1-year price target for VTRS of $13.3 , with forecasts ranging from a low of $10 to a high of $15 .
VTRS Lowest Price Target Wall Street Target
10 USD 29.62%
VTRS Average Price Target Wall Street Target
13.3 USD 72.82%
VTRS Highest Price Target Wall Street Target
15 USD 94.43%
Price
Max Price Target
Min Price Target
Average Price Target
151514141313121211111010998877Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.96% DIVIDEND YIELD
0.12 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.500.500.450.450.400.400.350.350.300.300.250.250.200.200.150.150.100.100.050.050.000.000.120.120.120.120.110.120.120.120.110.120.120.120.110.450.120.480.120.480.120.480.002021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Viatris Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
347 K USD 1
6-9 MONTHS
7.05 M USD 1
9-12 MONTHS
4.52 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Shareholders that Lost Money on Viatris Inc. (VTRS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144462&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144404&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"). accessnewswire.com - 1 week ago
VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. prnewswire.com - 1 week ago
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTRS NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144378&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / April 21, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period"). accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – VTRS NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144367&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Viatris Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144316&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
VTRS STOCK NEWS: Stockholders With Large Losses Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Viatris Inc. Class Action SAN DIEGO , April 21, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. prnewswire.com - 1 week ago
Shareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144304&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
VTRS LEGAL DEADLINE: Suffer Losses on Viatris Inc.? Contact BFA Law before June 3 Class Action Deadline NEW YORK, NY / ACCESS Newswire / April 21, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. accessnewswire.com - 1 week ago
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=144297&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
8. Profile Summary

Viatris Inc. VTRS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 9.21 B
Dividend Yield 0.96%
Description Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Contact 1000 Mylan Boulevard, Canonsburg, PA, 15317 https://www.viatris.com
IPO Date March 17, 1980
Employees 32000
Officers Mr. Paul B. Campbell Chief Accounting Officer, Senior Vice President & Corporate Controller Mr. Scott Andrew Smith Ph.D. Chief Executive Officer & Director Dr. Jeffrey Nau MMS, Ph.D. President of Viatris Eye Care Division Ms. Theodora Mistras Chief Financial Officer Mr. Brian S. Roman Chief Legal Officer Ms. Lara Ramsburg Chief Corporate Affairs Officer Mr. Ramkumar V. Rayapureddy Chief Information Officer Mr. Derek Glover Chief Quality Officer Mr. Andrew Enrietti Chief People Officer Mr. Menassie Taddese M.B.A. President of Emerging Markets